BiPar Sciences Raises $35 Million

BiPar Sciences Inc., a Brisbane, Calif.-based drug company focused on cancer therapies, has raised $35 million in Series B funding. Domain Associates led the deal, and was joined by return backers Vulcan Capital, Canaan Partners, PolyTechnos Venture-Partners, Asset Management Company and Quantum Technology Partners. BiPar is developing multiple compounds designed to inhibit PARP 1, an enzyme involved in cell repair and that is up-regulated in certain tumors. www.biparsciences.com